Financial news: Companies

Latest News

Live

09:36pm	165,000 Class A Ordinary Shares of Collective Acquisition Corp. II are subject to a Lock-Up Agreement Ending on 25-OCT-2026.	CI
09:27pm	Trump announces Audi will build $4 billion US factory in Georgia	RE
07:31pm	Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026	GL
Oct. 24	Inside the Trump-administration campaign to return Brazil's Bolsonaro clan to power	RE
Oct. 24	Trump set to announce plan by Audi to build US factory in Georgia, source says	RE
Oct. 24	Moderna, Inc. - Special Call
Oct. 24	Amgen Inc. Presents at 2026 European Society for Medical Oncology Annual Congress, Oct-24-2026 08:30 PM
Oct. 24	Teck Resources Limited Faces Strike Action At Highland Valley Copper Operations	CI
Oct. 24	Axon Announces Axon Body 5 and Axon Body 5 Pro	CI
Oct. 24	Axon Announces Body 5: Next-Generation Camera Built for the AI Era	PR
Oct. 24	Pfizer Inc. Announces Detailed Results Across Serotypes From A Phase 2 Study For Its Investigational 25-Valent Pneumococcal Conjugate Vaccine Candidate PF-07872412 In Infants	CI
Oct. 24	Astrazeneca Reports Positive Results from Volga Phase Iii Trial of Perioperative Imfinzi Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer	CI
Oct. 24	Amgen Announces IMDELLTRA in Combination with Imfinzi Reduces Risk of Death in First-Line Extensive Stage Small Cell Lung Cancer	CI
Oct. 24	Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026	BU
Oct. 24	IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial	BU
Oct. 24	Amgen drug combined with immunotherapy extends survival in lung cancer trial	RE
Oct. 24	IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER	PR
Oct. 24	Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer	BU
Oct. 24	Couche-Tard proposes up to $8 billion offer for Cumberland Farms, The Times reports	RE
Oct. 24	Johnson & Johnson Announces New Results From Phase 3 PROTEUS Substudy Of ERLEADA Treatment Before And After Surgery In High-Risk Prostate Cancer	CI
Oct. 24	Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors	CI
Oct. 24	Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer	PR
Oct. 24	Semtech Corporation Adds New Resilient Communications Building Blocks to Its Airlink 5G Networking Solutions	CI
Oct. 24	Bayer Reports Interim Analysis Results From The Phase III DASL-HiCaP Trial Of NUBEQA Plus ADT And Radiation Therapy In Prostate Cancer Patients At High Risk Of Recurrence	CI
Oct. 24	Kotak Mahindra Bank Limited, Q2 2027 Earnings Call, Oct 24, 2026
Oct. 24	Citi Receives Approval from the China Securities Regulatory Commission to Establish A Wholly-Owned Securities Company in China, Citigroup Securities Company Limited	CI
Oct. 24	US Metro Bancorp, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
Oct. 24	ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence	BU
Oct. 24	Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026	BU
Oct. 24	BMO Aggregate Bond Index ETF announces Monthly dividend, payable on November 03, 2026	CI
Oct. 24	BMO Equal Weight Banks Index ETF announces Monthly dividend, payable on November 03, 2026	CI
Oct. 24	Kotak Mahindra Bank Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
Oct. 24	VW labor dispute: Here's the roadmap for the coming weeks	DP
Oct. 24	Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer	BU
Oct. 24	Century Next Financial Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
Oct. 24	CULTURE CURRENT-Chase & Status on the upside of AI for music	RE
Oct. 24	UK pledges more funding to guard against artificial intelligence risks	AN
Oct. 24	Celcuity Inc. Presents Updated Results from the Pik3ca Mt Cohort of the Phase 3 Viktoria-1 Study in Patients with Hr+/Her2- Advanced Breast Cancer At the Esmo Congress 2026	CI
Oct. 24	Compass Therapeutics Announces Publication Of Phase 2/3 COMPANION-002 Results For Tovecimig In The Journal Of Clinical Oncology And Oral Presentation At ESMO 2026	CI
Oct. 24	BeOne Medicines Ltd. Presents New Data From Investigational Medicines Across Liver, Lung And Breast Cancers At ESMO 2026	CI
Oct. 24	Ukraine says Starshield back to normal, Musk says Kyiv violated terms	RE
Oct. 24	India's Kotak Bank Q2 profit rises 29%, beats estimates	RE
Oct. 24	BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026	BU
Oct. 24	Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial	RE
Oct. 24	Black Rock Coffee Bar Opens New Rancho Cucamonga Location in California	CI
Oct. 24	Zymeworks Inc. Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate Zw191 At ESMO Congress 2026	CI
Oct. 24	Eli Lilly And Company Presents First Clinical Data In Platinum-Sensitive Ovarian Cancer For Its Investigational, Next-Generation, FRa-Targeting ADC At ESMO 2026	CI
Oct. 24	Immatics N.V. Presents Updated Clinical Trial Data from Ongoing Phase 1B Study with IMA402 PRAME Bispecific and Phase 1 Study with IMA203CD8 PRAME Cell Therapy	CI
Oct. 24	Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026	PR
Oct. 24	Bayer Phase III Prostate Cancer Trial Cuts Metastasis Or Death Risk 58%	RE

Become a member to access more news

New member

No results match your criteria

Most Mentioned (24h)

JOHNSON & JOHNSON	-1.42%
BAYER AG	-0.52%
LVMH	-1.24%
AMGEN INC.	-1.79%
SPACEX (SPACE EXPLORATION TECHNOLOGIES)	+1.89%
ALIMENTATION COUCHE-TARD INC.	-1.48%
ELI LILLY AND COMPANY	-2.54%
VOLKSWAGEN AG	-0.87%
PFIZER INC.	-1.28%
KOTAK MAHINDRA BANK LIMITED	-1.70%

Headlines

	Ukraine says Starshield back to normal, Musk says Kyiv violated terms
	UK pledges more funding to guard against artificial intelligence risks
	Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial
	Amazon cloud capacity sold out through 2027, CEO Jassy says
	Why AI data centers are powering a boom in fuel-cell demand
	Health Care Down as Rotation From AI Cos Slows - Health Care Roundup
	Financials Down, Giving Back Some Earnings Gains - Financials Roundup
	Utilities Down as Treasury Yields Rebound - Utilities Roundup
	Eni Q3 Earnings, Sales Increase; Shares Rise
	Bayer Phase III Prostate Cancer Trial Cuts Metastasis Or Death Risk 58%

Stock markets for all

100% Free Registration

100% Free Registration